Arrowhead Pharmaceuticals Inc

NASDAQ: ARWR
$18.28
-$0.43 (-2.3%)
Closing Price on November 21, 2024

ARWR Stock Chart and Intraday Price

ARWR Stock Data

Asset Type Stock
Exchange NASDAQ
Currency USD
Country USA
Sector TRADE & SERVICES
Industry SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Address 225 SOUTH LAKE AVENUE, SUITE 1050, PASADENA, CA, US
Fiscal Year End September
Latest Quarter 12/31/2023
Market Cap 4,470.20M USD
Shares Outstanding 123,897,000
Arrowhead Pharmaceuticals Inc is a pioneering biopharmaceutical company focused on developing innovative medicines for challenging diseases. With a robust pipeline, it targets conditions like hypertriglyceridemia, non-alcoholic steatohepatitis, and various pulmonary diseases, among others. Arrowhead is actively conducting clinical trials across different phases to combat diseases such as chronic hepatitis B, liver diseases, and alpha-1 antitrypsin deficiency-related liver disease. The company collaborates with industry giants like Janssen Pharmaceuticals and Amgen, showcasing its commitment to advancing healthcare. Founded in 2003 and based in Pasadena, California, Arrowhead is at the forefront of medical research.

ARWR Articles

Monday's top analyst upgrades and downgrades included CyberArk Software, Diageo, Dish Network, Electronic Arts, Fox, Gilead Sciences, Molson Coors Beverage, O’Reilly Automotive, PacWest Bancorp,...
Thursday's top analyst upgrades and downgrades included Albertsons Companies, Alphabet, Apple, Coinbase Global, Danaher, Enphase Energy, GE HealthCare Technologies, General Electric, McDonald's,...
Wednesday's top analyst upgrades and downgrades included APA, Delta Air Lines, Generac, Lululemon Athletica, Microchip Technology, Paccar, Philip Morris International, Pinduoduo, Shopify,...
Thursday's top analyst upgrades and downgrades included Alcon, Array Technologies, AZEK, Boeing, Capital One Financial, Coinbase Global, Corning, Electronic Arts, Harley-Davidson, ON Semiconductor,...
24/7 Wall St. looks at some big analyst upgrades and downgrades that we have seen so far on Friday, including American Water Works, Carnival, Duke Energy, Okta and Zscaler.
The Friday afternoon analyst calls were focused on Biogen, Fortinet, Pinterest, Snap and more.
Arrowhead Pharmaceuticals has announced positive interim 24-week liver biopsy results in four subjects from its midstage study of ARO-AAT. Shares rallied on the news early Wednesday.